Picture of Artelo Biosciences logo

ARTL Artelo Biosciences Cashflow Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMicro CapNeutral

Annual cashflow statement for Artelo Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2020
August 31st
2021
August 31st
2022
December 31st
2023
December 31st
2024
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:10-K10-K10-K10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line-4.65-7.44-10.1-9.29-9.83
Depreciation
Non-Cash Items0.3481.542.290.4190.569
Unusual Items
Other Non-Cash Items
Changes in Working Capital-0.041-0.244-0.2150.6630.907
Change in Prepaid Expenses
Change in Accounts Payable
Change in Accrued Expenses
Change in Payable / Accrued Expenses
Cash from Operating Activities-4.35-6.14-8.01-8.21-8.35
Capital Expenditures0
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items-3.442.963.517.77
Sale/Maturity of Investment
Purchase of Investments
Cash from Investing Activities0-3.442.963.517.77
Financing Cash Flow Items0.003-0.0070
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Cash from Financing Activities1.9814.100.5670.112
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash-2.284.49-5.27-4.07-0.477